Ciclesonide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ciclesonide
Ciclesonide.svg
Ciclesonide ball-and-stick animation.gif
Systematic (IUPAC) name
2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a607008
Pregnancy cat.
Legal status
Routes nasal inhalation
Identifiers
CAS number 141845-82-1 YesY
ATC code R01AD13 R03BA08
PubChem CID 6918155
DrugBank DB01410
ChemSpider 5293368 YesY
UNII S59502J185 YesY
KEGG D01703 YesY
ChEMBL CHEMBL1201164 N
Synonyms (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
Chemical data
Formula C32H44O7 
Mol. mass 540.688 g/mol
 N (what is this?)  (verify)

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand name Alvesco for asthma and Omnaris/Omniair for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside the US are ongoing.[1] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[2] Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[3]

References[edit]

  1. ^ "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Retrieved 2009-07-30. [dead link]
  2. ^ "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies.". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30. 
  3. ^ Mutch, Elaine; Nave, Ruediger; McCracken, Nigel; Zech, Karl; Williams, Faith M. (2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology 73 (10): 1657–64. doi:10.1016/j.bcp.2007.01.031. PMID 17331475. 
  • Rossi S (Ed.) (2006). Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3